Merck & Co., Inc. (NYSE:MRK) Given New $140.00 Price Target at Royal Bank Of Canada

Merck & Co., Inc. (NYSE:MRK) had its price objective dropped by investment analysts at Royal Bank Of Canada from $145.00 to $140.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has a “sector perform” rating on the stock. Royal Bank Of Canada‘s price objective would suggest a potential downside of 6.73% from the stock’s current price.

A number of other brokerages also recently commented on MRK. Zacks Research downgraded shares of Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a research note on Monday, October 19th. Daiwa Securities Group raised shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price on the stock in a report on Wednesday, August 12th. Rothschild & Co Redburn raised their price target on Merck & Co., Inc. from $140.00 to $145.00 and gave the company a “buy” rating in a report on Monday, July 6th. Citigroup boosted their target price on shares of Merck & Co., Inc. from $125.00 to $145.00 and gave the stock a “neutral” rating in a research report on Monday, October 12th. Finally, Argus increased their price target on shares of Merck & Co., Inc. from $145.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, August 25th. Seventeen investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $152.96.

Merck & Co., Inc. Trading Up 2.6%

Shares of MRK stock traded up $3.77 during trading on Friday, hitting $150.10. 4,694,865 shares of the stock traded hands, compared to its average volume of 10,637,644. The firm’s fifty day moving average price is $146.89 and its 200-day moving average price is $126.49. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The firm has a market capitalization of $370.32 billion, a P/E ratio of 120.18, a price-to-earnings-growth ratio of 6.49 and a beta of 0.21. Merck & Co., Inc. has a 52-week low of $82.01 and a 52-week high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.09 by $0.40. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business had revenue of $18.09 billion for the quarter, compared to the consensus estimate of $17.33 billion. During the same period in the previous year, the firm earned $2.58 EPS. The business’s revenue was up 4.7% on a year-over-year basis. As a group, research analysts forecast that Merck & Co., Inc. will post 2.64 earnings per share for the current fiscal year.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP David Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the sale, the executive vice president directly owned 31,716 shares of the company’s stock, valued at approximately $4,084,069.32. The trade was a 62.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP David Maraldo sold 18,706 shares of the stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the transaction, the executive vice president owned 18,212 shares in the company, valued at $2,344,248.64. This trade represents a 50.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Merck & Co., Inc.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MRK. Bullseye Investment Management LLC acquired a new stake in shares of Merck & Co., Inc. during the 2nd quarter valued at about $27,000. Curry Webb Wealth Management LLC bought a new position in shares of Merck & Co., Inc. in the third quarter worth about $29,000. Horizons Wealth Management acquired a new stake in Merck & Co., Inc. in the 3rd quarter worth $30,000. Graney & King LLC grew its holdings in shares of Merck & Co., Inc. by 400.0% during the 2nd quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after purchasing an additional 200 shares in the last quarter. Finally, Montgomery Financial Services LLC acquired a new position in shares of Merck & Co., Inc. in the 2nd quarter valued at $41,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported adjusted third-quarter earnings of $2.49 per share, well above the $2.09 analyst consensus, while revenue rose 4.7% year over year to $18.09 billion versus expectations of $17.33 billion. Merck tops quarterly estimates, hikes profit outlook
• Positive Sentiment: Management raised its 2026 sales and adjusted profit outlook, signaling confidence that Keytruda, the newer Keytruda Qlex formulation and recently launched products can offset pressure from older medicines. Keytruda-related sales and WINREVAIR were notable growth drivers. Merck Q3 Earnings Call Highlights Pipeline Progress and Raised Outlook
• Positive Sentiment: Merck reported encouraging endometrial-cancer data: KEYTRUDA reduced the risk of disease progression, while sacituzumab tirumotecan produced positive late-stage results. The FDA also granted priority review to the latter’s application, strengthening the company’s pipeline outlook. Merck Turns Heads With Phase 3 Endometrial Cancer Data
• Positive Sentiment: Guggenheim raised its price target to $171 and maintained a Buy rating, implying further potential upside and adding support to the positive market reaction. Guggenheim Merck rating
• Neutral Sentiment: Merck remains attractive to income-oriented investors because of its dividend, but commentary cautions that dividend safety and yield should be assessed alongside the company’s patent and product-cycle risks. Merck dividend analysis
• Negative Sentiment: Investors continue to look beyond the earnings beat because Keytruda faces a patent cliff and generic headwinds beginning in 2027. Some reported revenue growth also benefited from the timing of customer purchases, suggesting underlying growth was less robust.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.